Fol. Biol. 2017, 63, 78-83

https://doi.org/10.14712/fb2017063020078

Influence of Cytochrome P450, ABC and SLC Gene Polymorphisms on Imatinib Therapy Outcome of Patients with Gastrointestinal Stromal Tumours (GIST)

Kacper Wasielewski1, B. Wasag1,2, A. Wozniak3, J. Pikiel4, A. Kowalik5, C. Osuch6, E. Bylina7, J. A. Siedlecki8, P. Rutkowski7, J. Limon1,2

1Department of Biology and Medical Genetics, Medical University of Gdansk, Gdansk, Poland
2Laboratory of Clinical Genetics, University Clinical Centre, Gdansk, Poland
3Laboratory of Experimental Oncology, Department of Oncology, KU Leuven and Department of General Medical Oncology, University Hospitals in Leuven, Leuven, Belgium
4Regional Oncology Centre, Gdansk, Poland
5Department of Molecular Diagnostics, Holycross Cancer Centre, Kielce, Poland
6Department of General Surgery, Medical Faculty, Jagiellonian University, Krakow, Poland
7Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland
8Department of Translational and Molecular Oncology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland

Received November 2016
Accepted January 2017

References

1. Angelini, S., Pantaleo, M. A., Ravegnini, G., Zenesini, C., Cavrini, G., Nannini, M., Fumagalli, E., Palassini, E., Saponara, M., Di, B. M., Casali, P. G., Hrelia, P., Cantelli-Forti, G., Biasco, G. (2013a) Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy. Pharmacol. Res. 68, 1-6. <https://doi.org/10.1016/j.phrs.2012.10.015>
2. Angelini, S., Soverini, S., Ravegnini, G., Barnett, M., Turrini, E., Thornquist, M., Pane, F., Hughes, T. P., White, D. L., Radich, J., Kim, D. W., Saglio, G., Cilloni, D., Iacobucci, I., Perini, G., Woodman, R., Cantelli-Forti, G., Baccarani, M., Hrelia, P., Martinelli, G. (2013b) Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica 98, 193-200. <https://doi.org/10.3324/haematol.2012.066480>
3. Blanke, C. D., Demetri, G. D., von Mehrem, M., Heinrich, M. C., Eisenberg, B., Fletcher, J. A., Corless, C. L., Fletcher, C. D., Roberts, P. J., Heinz, D., Wehre, E., Nikolova, Z., Joensuu, H. (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J. Clin. Oncol. 26, 620-625. <https://doi.org/10.1200/JCO.2007.13.4403>
4. Buchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno- Jones, S., Druker, B. J., Lydon, N. B. (2000) Abl proteintyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295, 139-145.
5. Casali, P. G., Blay, J. Y. (2010) Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21(Suppl 5), v98-102. <https://doi.org/10.1093/annonc/mdq208>
6. Chiang, N. J., Chen, L. T., Tsai, C. R., Chang, J. S. (2014) The epidemiology of gastrointestinal stromal tumors in Taiwan, 1998-2008: a nation-wide cancer registry-based study. BMC Cancer 14, 102. <https://doi.org/10.1186/1471-2407-14-102>
7. Corless, C. L., Fletcher, J. A., Heinrich, M. C. (2004) Biology of gastrointestinal stromal tumors. J. Clin. Oncol. 22, 3813-3825. <https://doi.org/10.1200/JCO.2004.05.140>
8. Corless, C. L., Barnett, C. M., Heinrich, M. C. (2011) Gastrointestinal stromal tumours: origin and molecular oncology. Nat. Rev. Cancer 11, 865-878. <https://doi.org/10.1038/nrc3143>
9. Debiec-Rychter, M., Sciot, R., Le, C. A., Schlemmer, M., Hohenberger, P., van Oosterom, A. T., Blay, J. Y., Leyvraz, S., Stul, M., Casali, P. G., Zalcberg, J., Verweij, J., Van, G. M., Hagemeijer, A., Judson, I. (2006) KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur. J. Cancer 42, 1093-1103. <https://doi.org/10.1016/j.ejca.2006.01.030>
10. Deenik, W., van der Holt, B., Janssen, J. J., Chu, I. W., Valk, P. J., Ossenkoppele, G. J., van der Heiden, I. P., Sonneveld, P., van Schaik, R. H., Cornelissen, J. J. (2010) Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib. Blood 116, 6144-6145. <https://doi.org/10.1182/blood-2010-07-296954>
11. Demetri, G. D., Wang, Y., Wehrle, E., Racine, A., Nikolova, Z., Blanke, C. D., Joensuu, H., von Mehrem, M. (2009) Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J. Clin. Oncol. 27, 3141-3147. <https://doi.org/10.1200/JCO.2008.20.4818>
12. Demetri, G. D., von Mehrem,M., Antonescu, C. R., DeMatteo, R. P., Ganjoo, K. N., Maki, R. G., Pisters, P. W., Raut, C. P., Riedel, R. F., Schuetze, S., Sundar, H. M., Trent, J. C., Wayne, J. D. (2010) NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J. Natl. Compr. Canc. Netw. 8(Suppl 2), S1-41. <https://doi.org/10.6004/jnccn.2010.0116>
13. Gastrointestinal Stromal Tumor Meta-Analysis Group (2010) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J. Clin. Oncol. 28, 1247-1253. <https://doi.org/10.1200/JCO.2009.24.2099>
14. Goettsch, W. G., Bos, S. D., Breekveldt-Postma, N., Casparie, M., Herings, R. M., Hogendoorn, P. C. (2005) Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur. J. Cancer 41, 2868-2872. <https://doi.org/10.1016/j.ejca.2005.09.009>
15. Harmsze, A. M., van Werkum, J. W., Ten Berg, J. M., Zwart, B., Bouman, H. J., Breet, N. J., van ‘t Hof, A. W., Ruven, H. J., Hackeng, C. M., Klungel, O. H., de Boer, A., Deneer, V. H. (2010) CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. Eur. Heart J. 31, 3046-3053. <https://doi.org/10.1093/eurheartj/ehq321>
16. Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D., von Mehrem, M., Joensuu, H., McGreevey, L. S., Chen, C. J., Van den Abbeele, A. D., Druker, B. J., Kiese, B., Eisenberg, B., Roberts, P. J., Singer, S., Fletcher, C. D., Silberman, S., Dimitrijevic, S., Fletcher, J. A. (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21, 4342-4349. <https://doi.org/10.1200/JCO.2003.04.190>
17. Hesselink, D. A., van Schaik, R. H., van der Heiden, I. P., van der Werf, M., Gregoor, P. J., Lindemans, J., Weimar, W., van Gelder, T. (2003) Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. 74, 245-254. <https://doi.org/10.1016/S0009-9236(03)00168-1>
18. Kim, D. H., Sriharsha, L., Xu, W., Kamel-Reid, S., Liu, X., Siminovitch, K., Messner, H. A., Lipton, J. H. (2009) Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin. Cancer Res. 15, 4750-4758. <https://doi.org/10.1158/1078-0432.CCR-09-0145>
19. Koo, D. H., Ryu, M. H., Ryoo, B. Y., Beck, M. Y., Na, Y. S., Shin, J. G., Lee, S. S., Kim, E. Y., Kang, Y. K. (2015) Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor. Cancer Chemother. Pharmacol. 75, 173-182. <https://doi.org/10.1007/s00280-014-2630-6>
20. Liegl-Atzwanger, B., Fletcher, J. A., Fletcher, C. D. (2010) Gastrointestinal stromal tumors. Virchows Arch. 456, 111-127. <https://doi.org/10.1007/s00428-010-0891-y>
21. Marrari, A., Trent, J. C., George, S. (2010) Personalized cancer therapy for gastrointestinal stromal tumor: synergizing tumor genotyping with imatinib plasma levels. Curr. Opin. Oncol. 22, 336-341. <https://doi.org/10.1097/CCO.0b013e32833a6b8e>
22. Miettinen, M., Lasota, J. (2001) Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 438, 1-12. <https://doi.org/10.1007/s004280000338>
23. Miettinen, M., Lasota, J. (2003) Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol. J. Pathol. 54, 3-24.
24. Miettinen, M., Lasota, J. (2013) Gastrointestinal stromal tumors. Gastroenterol. Clin. North Am. 42, 399-415. <https://doi.org/10.1016/j.gtc.2013.01.001>
25. Mucciarini, C., Rossi, G., Bertolini, F., Valli, R., Cirilli, C., Rashid, I., Marcheselli, L., Luppi, G., Federico, M. (2007) Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. BMC Cancer 7, 230. <https://doi.org/10.1186/1471-2407-7-230>
26. Nilsson, B., Bumming, P., Meis-Kindblom, J. M., Oden, A., Dortok, A., Gustavsson, B., Sablinska, K., Kindblom, L. G. (2005) Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - a population-based study in western Sweden. Cancer 103, 821-829. <https://doi.org/10.1002/cncr.20862>
27. Rubin, B. P., Heinrich, M. C., Corless, C. L. (2007) Gastrointestinal stromal tumour. Lancet 369, 1731-1741. <https://doi.org/10.1016/S0140-6736(07)60780-6>
28. Rubio-Casadevall, J., Borras, J. L., Carmona, C., Ameijide, A., Osca, G., Vilardell, L., Izquierdo, A., Galceran, J., Marcos- Gragera, R. (2014) Temporal trends of incidence and survival of sarcoma of digestive tract including gastrointestinal stromal tumours (GIST) in two areas of the northeast of Spain in the period 1981-2005: a population-based study. Clin. Transl. Oncol. 16, 660-667. <https://doi.org/10.1007/s12094-013-1131-0>
29. Tryggvason, G., Gislason, H. G., Magnusson, M. K., Jonasson, J. G. (2005) Gastrointestinal stromal tumors in Iceland, 1990-2003: the Icelandic GIST study, a populationbased incidence and pathologic risk stratification study. Int. J. Cancer 117, 289-293. <https://doi.org/10.1002/ijc.21167>
30. van Schaik, R. H. (2005) Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Invest. New Drugs 23, 513-522. <https://doi.org/10.1007/s10637-005-4019-1>
31. Wardelmann, E., Merkelbach-Bruse, S., Pauls, K., Thomas, N., Schildhaus, H. U., Heinicke, T., Speidel, N., Pietsch, T., Buettner, R., Pink, D., Reichardt, P., Hohenberger, P. (2006) Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin. Cancer Res. 12, 1743-1749. <https://doi.org/10.1158/1078-0432.CCR-05-1211>
32. Widmer, N., Decosterd, L. A., Leyvraz, S., Duchosal, M. A., Rosselet, A., Debiec-Rychter, M., Csajka, C., Biollaz, J., Buclin, T. (2008) Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br. J. Cancer 98, 1633-1640. <https://doi.org/10.1038/sj.bjc.6604355>
33. Yamakawa, Y., Hamada, A., Nakashima, R., Yuki, M., Hirayama, C., Kawaguchi, T., Saito, H. (2011) Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther. Drug Monit. 33, 244-250.
front cover

ISSN 0015-5500 (Print) ISSN 2533-7602 (Online)

Open access journal

Archive